Genmab — Share Issue/Capital Change 2014

May 14, 2014

Company Announcement

Copenhagen, Denmark; May 14, 2014 – Genmab A/S (OMX: GEN) will increase its
share capital by 58,064 shares as a consequence of the exercise of employee
warrants.

The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following price per share of nominally DKK 1:

-- 250 shares at DKK 26.75,
-- 150 shares at DKK 31.75,
-- 5,000 shares at DKK 40.41,
-- 1,375 shares at DKK 45.24,
-- 3,750 shares at DKK 46.74,
-- 8,500 shares at DKK 55.85,
-- 500 shares at DKK 66.60,
-- 645 shares at DKK 67.50,
-- 250 shares at DKK 68.65,
-- 2,250 shares at DKK 80.55,
-- 9,250 shares at DKK 86,
-- 1,000 shares at DKK 89.50,
-- 3,737 shares at DKK 101,
-- 20,000 shares at DKK 114, and
-- 1,407 shares at DKK 173.

Proceeds to the company are approx. DKK 5.0 million. The increase corresponds
to approx. 0.1 % of the company's share capital.

The increase includes the exercise of 2,250 warrants by board member Burton G.
Malkiel and 4,875 warrants by board member Tom Vink.

The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares give rights to dividends
and other rights in relation to the company as of subscription, i.e. inter alia
full rights to dividends for the financial year 2014. The new shares will be
listed on NASDAQ OMX Copenhagen after registration with the Danish Business
Authority. Genmab A/S' current share capital amounts to DKK 56,629,202 and will
after the capital increase be DKK 56,687,266. The capital increase is expected
to be finalized shortly.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company currently has one
marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications, a clinical pipeline with both late and early
stage programs, and an innovative pre-clinical pipeline. Genmab's technology
base consists of validated and proprietary next generation antibody
technologies - the DuoBody® platform for generation of bispecific antibodies,
and the HexaBody™ platform which creates effector function enhanced antibodies.
Genmab's deep antibody expertise is expected to provide a stream of future
product candidates. Partnering of selected innovative product candidates and
technologies is a key focus of Genmab’s strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies. For more information
visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo™; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody™
and UniBody®. Arzerra® is a registered trademark of the GSK group of companies.

Company Announcement no. 23
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark